HighPoint Advisor Group LLC boosted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 8.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,489 shares of the biopharmaceutical company’s stock after purchasing an additional 1,541 shares during the period. HighPoint Advisor Group LLC’s holdings in Bristol-Myers Squibb were worth $1,000,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Capital Financial Planning LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $28,000. Well Done LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $30,000. Riverview Trust Co acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $33,000. Portfolio Solutions LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $37,000. Finally, Gantzert Investment Co. LLC ADV acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $39,000. 74.27% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE:BMY opened at $45.57 on Monday. Bristol-Myers Squibb Co has a one year low of $44.30 and a one year high of $63.69. The company has a quick ratio of 1.50, a current ratio of 1.61 and a debt-to-equity ratio of 0.40. The company has a market cap of $75.25 billion, a PE ratio of 11.45, a price-to-earnings-growth ratio of 2.37 and a beta of 0.79.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a dividend yield of 3.60%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is 41.21%.
BMY has been the subject of several research reports. BMO Capital Markets restated a “buy” rating and issued a $60.00 price objective on shares of Bristol-Myers Squibb in a research report on Thursday, January 3rd. Bank of America set a $53.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Friday, January 25th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Monday, April 8th. Morgan Stanley set a $54.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Thursday, December 20th. Finally, ValuEngine cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Friday, January 4th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and six have assigned a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $59.13.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Article: What is insider trading?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.